IDEAYA Biosciences IDYA 深 滬
等待開盤 09-25 09:30:00 美东时间
36.70
-0.760
-2.03%
華盛通- 最 高37.78
- 今 開37.46
- 成交量 69.04万股
- 最 低 35.59
- 昨 收 37.46
- 總市值 35.41亿
- 52周最高 42.68
- 市盈率 靜 --
- 換手率 0.72%
- 52周最低 26.05
- 委 比 17.30%
- 總股本 9648.95万
- 歷史最高 47.735
- 量 比 0.68
- 振 幅 5.85%
- 歷史最低 2.95
- 每 手 1
- 風險率 3.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57
Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $54 to $57.
09-09 21:12
美股大行评级 | 美银上调微软目标价从500美元升至600美元；BlossomHill获小摩等多家大行首予买入评级
今日重点评级关注：BTIG：维持Kazia Therapeutics"买入"评级，目标价从34美元升至40美元；摩根大通：维持Annexon"超配"评级，目标价从10美元升至14美元
09-02 14:07
IDEAYA Reaches FDA Agreement On Late-Stage Trial Plan For Lung Cancer Drug, Plans Phase 3 Lung Cancer Study For IDE849 By Year-End 2026
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a successful FDA Type C meeting to determine the Phase 3 registrational trial design for IDE849, a potential best-in-class delta-like ligand 3...
08-31 18:05
Moderna(MRNA.US)mRNA癌症疫苗重大突破引爆市场情绪！生物科技板块估值重估可能才刚开始
生物科技行业在很大程度上受到临床事件的驱动——一项三期临床试验的成功或失败，不仅可以推动直接参与其中的公司股价大幅波动，也可能影响它们所代表的整个治疗技术类别...
08-25 11:45
IDEAYA Biosciences Enters Clinical Collaboration With Roche's Genentech To Evaluate The Efficacy And Safety Of IDE892, Its Investigational MTA-Cooperative PRMT5 Inhibitor, In Combination With GDC-7035, Genentech's KRAS G12D Inhibitor, In Patients With Pancreatic Ductal Adenocarcinoma
Collaboration to to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class MTA-cooperative PRMT5 inhibitor, in combination with GDC-7035 (RG6620), Genentech's KRAS G12D inhibitor, in patients with pancreatic ductal adenocarcinoma (PDAC) harboring both an MTAP-deleti...
08-19 18:03
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, Genentech's Phase 1 KRA...
08-19 18:00
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60
Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $58 to $60.
08-05 21:20
IDEAYA 2026年第二季度财报：注册性试验达标，现金增至12.4亿美元
IDEAYA（IDYA）2026年第二季度合作收入890万美元，净亏损1.125亿美元、每股亏损1.22美元；OptimUM-02达到主要终点，融资后现金及证券增至约12.4亿美元。
08-05 06:20
